{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-070838","form_type":"8-K","ticker":null,"cik":"0001567514","company_name":"Intra-Cellular Therapies, Inc.","filed_at":"2024-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.645519+00:00","generated_at":"2026-06-04T13:21:42.384748+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Intra-Cellular Therapies promotes Michael Halstead to President; CFO Hineline to retire","bullets":["Michael Halstead, former EVP & General Counsel, promoted to President effective March 19, 2024.","Halstead's base salary increased to $636,540; receives 36,717 time-based RSUs and 12,240 performance-based RSUs.","CFO Lawrence Hineline intends to retire after 20+ years; company has initiated external search for successor.","Hineline will remain through transition; departure not due to any disagreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-070838","json":"https://secwatch.observer/filing/0001193125-24-070838.json","markdown":"https://secwatch.observer/filing/0001193125-24-070838.md","text":"https://secwatch.observer/filing/0001193125-24-070838.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1567514/000119312524070838/0001193125-24-070838-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1567514/000119312524070838/d800974d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:21:42.384748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8bb7d699ba","claim":"Michael I. Halstead was appointed as President at Intra-Cellular Therapies, Inc..","evidence_excerpt":"On March 19, 2024, Intra-Cellular Therapies, Inc. (the “Company”) announced that the Company promoted Michael I. Halstead, the Company’s Executive Vice President, General Counsel and Secretary, to the role of President, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567514/000119312524070838/0001193125-24-070838-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"promoted"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"8bfcb0bcbc","claim":"Lawrence J. Hineline departed as Chief Financial Officer at Intra-Cellular Therapies, Inc..","evidence_excerpt":"On March 14, 2024, Lawrence J. Hineline notified the Company that he intends to retire as Senior Vice President of Finance, Chief Financial Officer, Treasurer and Assistant Secretary of the Company following the appointment of his successor as Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1567514/000119312524070838/0001193125-24-070838-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"intends to retire"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}